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Summary
AIMS OF THE STUDY: Anticoagulation of patients with
screen-detected atrial fibrillation may prevent ischaemic
strokes. The STAR-FIB study programme aims to deter-
mine the age- and sex-specific prevalence of silent atrial
fibrillation and to develop a clinical prediction model to
identify patients at risk of undiagnosed atrial fibrillation in
a hospitalised patient population.
METHODS: The STAR-FIB study programme includes a
prospective cohort study and a case-control study of hos-
pitalised patients aged 65–84 years, evenly distributed for
both age and sex. We recruited 795 patients without atri-
al fibrillation for the cohort study (49.2% females; medi-
an age 74.8 years). All patients had three serial 7-day
Holter ECGs to screen for silent atrial fibrillation. The pri-
mary endpoint will be any episode of atrial fibrillation or
atrial flutter of ≥30 seconds duration. The age- and sex-
specific prevalence of newly diagnosed atrial fibrillation
will be estimated. For the case-control study, 120 patients
with paroxysmal atrial fibrillation were recruited as cases
(41.7% females; median age 74.6 years); controls will be
randomly selected from the cohort study in a 2:1 ratio.
All participants in the cohort study and all cases were
prospectively evaluated including clinical, laboratory,
echocardiographic and electrical parameters. A clinical
prediction model for undiagnosed atrial fibrillation will be
derived in the case-control study and externally validated
in the cohort study.
CONCLUSIONS: The STAR-FIB study programme will es-
timate the age- and sex-specific prevalence of silent atrial
fibrillation in a hospitalised patient population, and develop
and validate a clinical prediction model to identify patients
at risk of silent atrial fibrillation.
Keywords: atrial fibrillation, screening, gender, paroxys-
mal, subclinical, silent, prospective, cohort, case-control,
hospitalised
Introduction
Atrial fibrillation increases the risk of arterial thromboem-
bolism and is associated with increased morbidity and
mortality [1]. The guidelines of the European Society of
Cardiology advise anticoagulation therapy in the presence
of atrial fibrillation and a CHA2DS2-VASc score ≥1 in men
and ≥2 in women [2]. The European guidelines and the
AF-Screen International Collaboration recommend oppor-
tunistic screening by pulse taking or ECG strip for indi-
viduals aged ≥65 years, and systematic screening in pa-
tients aged ≥75 years or at high stroke risk [2, 3]. The
incidence of screen-detected atrial fibrillation, i.e., atrial
fibrillation diagnosed by specific screening efforts, is con-
sistently higher with systematic screening than with oppor-
tunistic or no screening [4, 5]. Most patients with screen-
detected atrial fibrillation by repeat patient-activated ECG
or Holter-ECG have a clinically relevant atrial fibrillation
burden [6]. Therefore, patients with screen-detected atrial
fibrillation are likely to have the same benefit from antico-
agulation therapy as those with incidentally detected atrial
fibrillation and symptomatic atrial fibrillation, with signif-
icant reductions in stroke and death [3, 7].
Screen-detected atrial fibrillation has to be differentiated
from atrial fibrillation detected by implantable devices
such loop recorders, pacemakers and implantable car-
dioverter defibrillators (ICDs) [8–11]. These devices can
record single atrial fibrillation episodes as short as 2 min-
utes and may detect atrial fibrillation in patients with a
very low atrial fibrillation burden. The European guide-
lines recommend anticoagulation therapy in implanted de-
vice-detected atrial high-rate episodes only after ECG con-
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evidence, no clear recommendation for anticoagulation
therapy is stated in the guidelines regarding atrial high-rate
episodes without ECG confirmation of atrial fibrillation [2,
9]. Adequately powered, randomised, controlled trials of
anticoagulation therapy in patients with both screen-detect-
ed [12–14] atrial fibrillation as well as implanted device-
detected [15, 16] atrial high-rate episodes are underway
and will ultimately settle the question.
The prevalence of silent atrial fibrillation, i.e., undiagnosed
or subclinical atrial fibrillation, depends on the setting,
screening method, population studied and individual pa-
tient characteristics [3, 17, 18]. Most atrial fibrillation
screening studies have been carried out in primary care
clinics, in pharmacies, by other non-medical healthcare
practitioners or in the general population. Age, biomarkers
and other patient characteristics have been included in var-
ious prediction models for screen-detected atrial fibrilla-
tion [8, 10, 11, 19–22]. These prediction models, together
with the reported prevalence of screen-detected atrial fib-
rillation, form the basis for the design of large-scale, cost-
efficient and successful screening programmes.
However, hospitalised patient populations have generally
been exempt from screening studies, although they have a
high prevalence of already known atrial fibrillation [23].
The prevalence of silent atrial fibrillation may be high in
this patient population and justify intensified screening ef-
forts. Prediction models for screen-detected atrial fibrilla-
tion developed and validated in other settings may need to
be adapted for hospitalised patient populations.
Methods
The STAR-FIB study programme comprises a hospital-
based, prospective cohort study and a hospital-based, case-
control study. The programme has four aims:
1. To determine the age- and sex-specific, and overall
prevalence of silent atrial fibrillation in the prospective
cohort study.
2. To develop and internally validate a clinical prediction
model based on clinical, laboratory, echocardiographic
and electrical parameters in the case-control study to
discriminate between cases with paroxysmal atrial fib-
rillation and controls without atrial fibrillation.
3. To validate the clinical prediction model in the
prospective cohort study in predicting the detection of
silent atrial fibrillation during the screening period.
4. To assess the long-term incidence of newly diagnosed
atrial fibrillation in the prospective cohort study and
validate the clinical prediction model in the extended
follow-up of the prospective cohort study.
Between19 January 2015 and 26 June 2019, we recruited
inpatients aged ≥65 to <85 years from the Departments of
General Internal Medicine, Cardiology and Ophthalmolo-
gy at our tertiary care hospital for both the prospective co-
hort and case-control study. The study was approved by
the independent research ethics committee of the Canton
of Bern (KEK-BE 257/14). All study participants provided
written informed consent.
Prospective cohort study
Patients were eligible for the prospective cohort study if
they were in sinus rhythm and did not have a previous di-
agnosis of atrial fibrillation (see table 1 for detailed eligi-
bility criteria). Patients with repeat admissions were eval-
uated only during their first admission. During recruitment
periods, all inpatients of a targeted sex- and age-specific
subgroup were evaluated, with reasons for ineligibility for
the cohort study and unwillingness to participate recorded
in a recruitment log.
We intended to include 100 males and 100 females in each
of four age bands of ≥65 to <70, ≥70 to <75, ≥75 to <80,
and ≥80 to <85 years, corresponding to a total of 800 pa-
tients in the prospective cohort study. Recruitment of male
participants aged <80 years was faster than recruitment of
the remaining subgroups. We therefore randomly select-
ed calendar weeks during which males aged <80 years
would be recruited, whereas the remaining subgroups were
continuously recruited. Recruitment was capped for each
subgroup once the necessary number of participants was
reached.
There were 44,636 hospital admissions during periods of
study recruitment. Of these, we assessed 11,470 patients
for eligibility for the cohort study (fig. 1). We excluded
2525 patients because of known atrial fibrillation (22.0%)
and 3112 patients for other, prespecified exclusion criteria
(27.1%; table 1). Of the remaining 5833 eligible patients,
2551 patients could not be approached for study participa-
Table 1: Overview of inclusion and exclusion criteria.
Cohort study Cases of case-control study
Inclusion criteria Eight subgroups, stratified for age and gender (N=100 for each
subgroup)
– Males aged ≥65 and <70 years
– Males aged ≥70 and <75 years
– Males aged ≥75 and <80 years
– Males aged ≥80 and <85 years
– Females aged ≥65 and <70 years
– Females aged ≥70 and <75 years
– Females aged ≥75 and <80 years
– Females aged ≥80 and <85 years
– Patients aged ≥65 and <85 years
– Diagnosis of paroxysmal atrial fibrillation (not solely in the setting of
thyrotoxicosis, severe systemic infection or after major cardiac surgery)
– ECG documentation of atrial fibrillation
– In sinus rhythm at baseline visit
Specific exclusion criteria – Diagnosis of atrial fibrillation
– Patients with an indication for long–term anticoagulation therapy
– History of catheter ablation of atrial fibrillation
– Non-paroxysmal atrial fibrillation
General exclusion criteria – History of acute coronary syndrome, percutaneous coronary revascularisation, transcutaneous aortic valve replacement, major cardiac or
non-cardiac surgery or hospitalisation due to heart failure within the previous 3 months
– Patients with planned percutaneous coronary revascularisation, transcutaneous aortic valve replacement, or major cardiac or non-cardiac
surgery
– Patients on class I or class III antiarrhythmic drugs
– Patients with a projected life expectancy of less than 1 year
– Patients incapable of providing written informed consent
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Figure 1: Flow chart showing recruitment of participants for the cohort study and for the case-control study (grey shaded area).
tion for various reasons (43.7%; fig. 1), 2487 refused to
participate (42.6%) and 795 consented to inclusion in the
prospective cohort study (13.6%).
We included 391 females (49.2%) and 404 males. We were
unable to reach the necessary target number of females
aged ≥80 years during the recruitment period; only 91 par-
ticipants were recruited (fig. 2). Conversely, 102 males
were recruited in age groups ≥70 to <75 and ≥75 to <80
years. The median age of the entire cohort was 74.8 years
(interquartile range 69.9 to 79.7). Figure 2 shows the cu-
mulative recruitment over time overall (top) and by age
and sex (bottom).
The primary endpoint of the cohort study is a diagnosis of
atrial fibrillation or atrial flutter of more than 30 seconds
duration during a 7-day Holter ECG, on a rhythm strip or
on any conventional 12-lead ECG up to the last follow-
up visit, according to the definition of the European atrial
fibrillation guidelines [2]. All primary endpoints are adju-
dicated by two experienced electrophysiologists. Included
participants underwent three 7-day Holter ECGs to screen
for silent atrial fibrillation. The first 7-day Holter ECG was
recorded upon hospital discharge. The second and third
7-day Holter ECGs were recorded during two further study
visits 2 and 4 months after hospital discharge – the first
24 hours of the second 7-day Holter ECG were analysed
separately as a 24-hour Holter ECG to calculate prema-
ture atrial complex count and number, and the longest du-
Figure 2: Cumulative recruitment over time overall for the cohort
study and for the cases of the case-control study (top) and by age
and sex subgroups for the cohort study (bottom).
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ration of atrial tachycardias. If atrial fibrillation was diag-
nosed, the subsequent 7-day Holter ECGs were cancelled,
except for the 24-hour Holter ECG during the 2-month
visit. In the case of an incidental finding during a 7-day
Holter ECG, the patients were notified and offered spe-
cialist evaluation. Complete recordings of all 7-day Holter
ECGs were analysed using the Pathfinder SL® software
(Spacelabs Healthcare, Issaquah, WA, USA) with addi-
tional manual confirmatory analysis by experienced study
staff, as previously described [24]. Specificity and sensitiv-
ity of the software were 80.2% and 98.5%, respectively, in
previous analyses by our group [24]. All software-detected
episodes of atrial fibrillation were manually confirmed or
rejected by experienced study staff supervised by a board-
certified electrophysiologist. To further improve sensitivi-
ty, all Holter recordings were additionally analysed man-
ually to identify episodes of atrial fibrillation missed by
the software. The number and duration of atrial fibrilla-
tion episodes, as well as the number and duration of non-
sustained and sustained atrial tachycardias, were assessed
manually. Premature atrial complexes were defined as a re-
duction of the RR interval of ≥25% compared with the pre-
vious normal RR interval and with normal or aberrant QRS
morphology. Premature atrial complex count was assessed
automatically after manual confirmation of normal or aber-
rant QRS morphology. For logistical reasons, study staff
could not be blinded to baseline characteristics, including
age and sex.
During the 2-month study visit, a 12-lead ECG, a signal-
averaged ECG, measurement of blood pressure and heart
rate, advanced echocardiography and blood sampling were
performed. Examinations were only performed if partici-
pants were in stable condition, without intercurrent illness
(table 2). Appendix 1 describes all study procedures in
detail. All cohort participants and/or their physicians will
subsequently be contacted after 30 and 60 months during
an extended follow-up to ascertain the following clinical
endpoints: diagnosis of atrial fibrillation and/or atrial flut-
ter; death; anticoagulation therapy; acute ischaemic stroke
and/or transient ischemic attack; pacemaker or ICD im-
plantation.
Case-control study
Cases were included from the same source population as
the participants in the prospective cohort study. To be eli-
gible as cases, participants had to have ECG-documented
paroxysmal atrial fibrillation but be in sinus rhythm at the
time of inclusion (see table 1 for inclusion and exclusion
criteria). We assessed 5259 patients with atrial fibrillation
according to medical records for eligibility as cases for the
case-control study; 2525 of these had been excluded from
the cohort study (48.0%) and 2734 were directly recruit-
ed from the remainder of the source population (52.0%;
fig. 1). We excluded 1013 patients because they did not
fulfil age criteria (19.3%) and 2978 because they fulfilled
other, prespecified exclusion criteria (56.6%; table 1). Of
the remaining 1268 eligible patients, 770 patients could not
be approached for study participation for various reasons
(60.7%; fig. 1), 378 refused to participate (29.8%), and 120
consented to be included as cases for the case-control study
(9.5%). Of these, 50 were females (41.7%), and the median
age was 74.6 years (interquartile range 69.3 to 79.2). All
cases were in sinus rhythm at inclusion and an ECG with
documented atrial fibrillation available. Figure 2 shows the
cumulative recruitment over time for the cases of the case-
control study (top).
Cases were scheduled for a single study visit within 3
months after hospital discharge, if in stable condition with-
out intercurrent illness. During this visit, a 12-lead ECG,
a signal-averaged ECG, measurement of blood pressure
and heart rate, advanced echocardiography, blood sam-
pling and a 24-hour Holter ECG were performed (table 2).
Appendix 1 describes all study procedures in detail.
Participants in the prospective cohort study will serve as
controls. Within each sex and age subgroup and clinical
department (internal medicine, ophthalmology and cardi-
ology), cases and controls will be randomly selected in a
1:2 ratio. To minimise spectrum bias [25, 26], participants
in the prospective cohort study will be eligible as controls
irrespective of the presence or absence of atrial fibrillation
found during follow-up.
Sample size considerations
For the prospective cohort study, we assumed an incident
diagnosis of silent atrial fibrillation in 5% of participants,
based on the study by Engdahl et al. [27], with a strong
positive association with age. With 200 patients included
in each age subgroup (100 males and 100 females each),
we will be able to estimate the frequency of incident diag-
noses of atrial fibrillation in each age subgroup with suf-
ficiently narrow 95% confidence intervals (CIs). The an-
ticipated frequency will increase from 1.0% in participants
aged 65 to 69 years (95% CI 0.3 to 3.6%) to 10.0% in par-
ticipants aged 80 to 84 years (95% CI 6.6% to 14.9%).
Table 2: Overview of study procedures.
Cohort study Cases of case-control study
Baseline visit – Informed consent
– Baseline case report form
– Informed consent
– Baseline case report form
– Blood samples
– Advanced echocardiography
– ECG and signal-averaged ECG
– 24-hour Holter ECG
Hospital discharge – First 7-day Holter ECG – n/a
2-month visit – Second 7-day Holter ECG
– Blood samples
– Advanced echocardiography
– ECG and signal-averaged ECG
– n/a
4-month visit – Third 7-day Holter ECG – n/a
30 months follow-up – Telephone interview – n/a
60 months follow-up – Telephone interview – n/a
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For the case-control study, the analysis of 120 cases and
240 controls, using analytical weights to achieve inde-
pendence of the age/sex distribution from the recruitment
strategy (see below), will afford more than 80% power to
detect an odds ratio of 1.8 for the association of paroxys-
mal atrial fibrillation with a dichotomous risk factor, which
has a prevalence of 40%, at a two-sided alpha of 5%.
Statistical analyses
Using data from the recruitment log, we will estimate the
age- and sex-specific, and overall prevalence of any type of
atrial fibrillation and of paroxysmal atrial fibrillation with
95% CIs for the source population of inpatients aged ≥65
to <85 years hospitalised at the participating departments
between 19 January 2015 and 26 June 2019. To derive
these estimates, we will use extrapolations based on age/
sex-specific recruitment fractions, assuming that those as-
sessed for eligibility and those not assessed were similar in
terms of baseline characteristics and consent rates. We will
consider only the first hospital admission per patient dur-
ing the study period. For each age/sex subgroup, the vari-
ances of prevalence estimates will be obtained as the sum
of the relevant variances of estimates used to derive preva-
lence [28]. Then, we will use fixed-effect linear regression
with the inverse of the variance as analytical weights to de-
rive p-values for difference in prevalence between males
and females, and p-values for trend across age subgroups.
For the prospective cohort study, we will estimate the age-
and sex-specific prevalence of newly diagnosed atrial fib-
rillation and corresponding 95% CIs based on the number
of participants in the prospective cohort study diagnosed
with atrial fibrillation up to the last follow-up visit. To de-
rive the age/sex-specific prevalence, and the overall preva-
lence of newly diagnosed atrial fibrillation, reflecting the
true age and sex distribution of potentially eligible inpa-
tients hospitalised during the entire recruitment period, we
will use the svy family of commands in Stata that take
the complex recruitment strategy into account based on
appropriate analytical weights [29]. The use of analytical
weights will result in independence of estimates from the
age/sex distribution targeted during recruitment. Weights
will be calculated separately for each age-, sex- and depart-
ment-specific subgroup, dividing the total number of 1620
possible recruitment days during the study by the number
of days used to recruit participants in the respective sub-
group. A hypothetical participant of a specific subgroup,
who we recruited during a cumulative period of 600 days,
would therefore receive twice the analytical weight of a
hypothetical participant in another subgroup, who we re-
cruited during a cumulative period of 1200 days.
The case-control study will be analysed using a weighted
logistic regression model based on an analogous approach
[29] to achieve independence of the age/sex distribution
from the recruitment strategy of controls and from the
matching strategy. We will perform univariate analyses
to examine associations between clinical, laboratory,
echocardiographic and electrical parameters and atrial fib-
rillation. The final multivariable model intended for clin-
ical prediction will be based on stepwise backward selec-
tion using the Akaike Information Criterion to eliminate
variables, irrespective of significance levels of the ob-
served association [30]. Discrimination of the final clinical
prediction model will be internally validated based on a
minimum of 200 bootstrap samples with replacement [30],
and externally validated based on the primary endpoint of
the prospective cohort study. Participants of the prospec-
tive cohort study will be eligible as controls in the case-
control study irrespective of the presence or absence of
atrial fibrillation found during follow-up, therefore incor-
poration bias should not occur [31]. External validation
will subsequently be repeated using data from the extended
follow-up of the prospective cohort study. Parameters in
the case-control study will be ranked based on univariate
analyses, using the absolute magnitude of the log odds ra-
tio comparing the presence or absence of a dichotomous
parameter, or the log odds ratio for two standard deviations
increase of a continuous parameter to ensure comparability
of scales [32]. We will account for missing data in the base-
line covariates using multiple imputation to create 20 im-
puted datasets, with baseline characteristics and presence
or absence of screen-detected atrial fibrillation as variables
in the imputation model. All associations will be report-
ed as odds ratios with corresponding two-sided 95% CIs
and two-sided p-values. All statistical analyses will be per-
formed using Stata 15.1 (StataCorp, College Station, TX,
United States).
Discussion
Strategies to diagnose silent atrial fibrillation and initiation
of anticoagulation therapy are essential for stroke preven-
tion. European and international guidelines advocate sys-
tematic screening in patients at high stroke risk [3, 33]. The
screening yield depends on the prevalence of silent atri-
al fibrillation in the screened population and the diagnos-
tic performance of the test [34]. Single time-point screen-
ing by ECG recording is the most widely used screening
tool for silent atrial fibrillation, with a screening yield of
1% overall and 1.4% in subjects aged >65 years [35]. With
more advanced screening strategies, using Holter monitor-
ing, ECG patches [5, 36], repeat ECG self-recording with
dedicated devices [27, 37] or smartphone-based gadgets
[38, 39], the screening yield increases to 5% and higher,
depending on the population studied, monitoring duration
and frequency. With implanted cardiac monitors, typically
used in populations at high risk of stroke, screening yield
reaches 20–30% if monitoring is continued for 2–3 years
[8, 10, 11, 40, 41]. Atrial fibrillation screening studies have
mostly been performed in larger communities [27, 36, 37],
primary care [4], outpatient clinics [9], pharmacies [42] or
consumer volunteers [38, 39]. No screening study in hos-
pitalised patient populations has been reported, except for
one study of single time-point screening comparing two
handheld ECG devices [43]. In this study, atrial fibrilla-
tion was detected in one of 206 patients without previously
known atrial fibrillation on a cardiology ward and in two
of 80 patients on a geriatric ward.
The STAR-FIB study will be the first study to report the
prevalence of silent atrial fibrillation in a hospitalised pa-
tient population aged ≥65 years using a more advanced
screening strategy. Although implantable cardiac monitors
may be able to more precisely estimate the prevalence of
silent atrial fibrillation, they are invasive and costly. Re-
peat 7-day Holter ECGs are a noninvasive, affordable and
widely available alternative, providing continuous record-
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ings of two ECG channels for 7 days. According to data
from implanted cardiac monitors, the sensitivity to diag-
nose silent atrial fibrillation with three repeat 7-day Holter
ECGs is about 33%, whereas the sensitivity is only about
8% with twice daily recordings of a 30 seconds ECG strip
for 2 weeks [17]. A screening strategy of three repeat 7-day
Holter ECGs within 4 months therefore represents a rea-
sonable balance between sensitivity and costs.
Most screening studies are not able to adequately describe
the prevalence of already known atrial fibrillation in the
screened population, because of a selection bias [27, 37].
However, the prevalence of known atrial fibrillation is im-
portant, as it may also influence the prevalence of silent
atrial fibrillation. The prevalence of atrial fibrillation in-
creases with age and several studies have reported an as-
sociation of age with prevalence of silent atrial fibrillation.
However, no study has investigated in detail the interplay
of age with the prevalence of known atrial fibrillation and
prevalence of silent atrial fibrillation. Through the recruit-
ment log of the STAR-FIB cohort study we will be able to
precisely estimate the age- and sex-specific prevalence of
known atrial fibrillation in the source population of the co-
hort study, to which the prevalence of silent atrial fibrilla-
tion will add.
Prediction models may be useful to increase the yield of a
screening programme and to improve its cost-efficiency by
devoting screening efforts to subpopulations at higher risk
of silent atrial fibrillation [34]. Existing prediction mod-
els mostly use age, biomarkers and other, widely available
clinical patient characteristics [8, 10, 11, 19–22, 44, 45].
The STAR-FIB study will expand these prediction mod-
els to a hospitalised patient population. In addition to clin-
ical patient characteristics and biomarkers, the STAR-FIB
study will explore other advanced echocardiographic and
electrical markers, such as atrial electromechanical delay
[46], excessive atrial ectopy [47], or signal-averaged P-
wave duration [48], as risk factors for the detection of un-
diagnosed atrial fibrillation.
The STAR-FIB study programme aimed at simultaneously
recruiting participants for a hospital-based prospective co-
hort study and a case-control study. For the cohort study,
we included 795 patients, using a complex recruitment
strategy that ensured approximately equal numbers of
males and females, and even age distributions between 65
and 84 years. The representation of octogenarians and fe-
males is one of the unique features of STAR-FIB. The 120
cases for the case-control study originate from the same
source population as the cohort study and are representa-
tive of patients with undiagnosed atrial fibrillation, as they
all had paroxysmal atrial fibrillation, were not on antiar-
rhythmic drugs, without previous ablation procedures and
in sinus rhythm when undergoing assessments. Controls
will be participants of the cohort study, randomly select-
ed on a 2:1 basis with cases. Incorporation bias [31] will
be avoided by considering participants of the prospective
cohort study as controls, irrespective of the subsequent de-
tection of atrial fibrillation during follow-up. The complex
recruitment strategy will be taken into account by apply-
ing an appropriate weighting scheme for the analysis of the
case-control study to achieve independence of the age/sex
distribution from recruitment and matching strategies.
The STAR-FIB study programme has several limitations.
First, it is a single centre study. Second, results will only
be applicable to a hospitalised patient population aged be-
tween 65 and 84 years. Third, additional, external valida-
tion of the results will be necessary in independent patient
populations. Fourth, the implantation of a loop recorder
would be the gold standard to screen for silent atrial fibril-
lation and with repeat 7-day Holter ECGs the prevalence
of silent atrial fibrillation will be underestimated.
In conclusion, the STAR-FIB study programme will clarify
the prevalence of silent atrial fibrillation in a hospitalised
patient population aged 65 to 84 years. It will thoroughly
investigate various clinical, electrical, laboratory and
echocardiographic parameters of atrial function and devel-
op a clinical prediction model for hospitalised patients at
risk of undiagnosed atrial fibrillation.
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Appendix 1
Study procedures
Baseline case report form
The following clinical parameters will be assessed: age;
gender; hypertension; diabetes mellitus; history of is-
chaemic stroke or transient ischaemic attack; coronary
artery disease (defined as ≥50% coronary artery stenosis;
previous myocardial infarction; previous coronary artery
bypass grafting or coronary angioplasty); peripheral arte-
rial disease; history of congestive heart failure; weight;
height; body mass index; CHADS score; CHA2DS2-VASc
score.
Blood sampling
The following laboratory parameters will be assessed: cre-
atinine; haemoglobin; high-sensitivity C-reactive protein
(hsCRP); brain natriuretic peptide (BNP); high-sensitivity
troponin T (hsTnT). In the cohort study the fibrin D-dimer
levels will additionally be assessed.
Electrocardiography
A standard 12-lead ECG will be recorded with assessment
of the RR, PR and QT interval, QRS width, presence of left
or right bundle branch block. The QTc interval will be cal-
culated using the Bazett formula.
Signal-averaged ECG (SAECG)
A signal-averaged ECG of the P-wave will be recorded by
averaging 250 sinus rhythm P-waves. The total duration of
the signal-averaged P-wave will be measured.
A signal-averaged ECG of the QRS-complex will be
recorded by averaging 150 sinus rhythm QRS complexes.
The total duration of the signal-averaged QRS complex
will be measured.
Clinical parameters
Blood pressure and resting heart rate will be measured.
Echocardiography
The left ventricular dimensions and wall thickness will be
determined in the parasternal long-axis view, as well as left
atrial diameter and 2D- and 3D-volume from the paraster-
nal long-axis view, 4- and 2-chamber view. The left ven-
tricular ejection fraction will be assessed from the apical
4- and 2-chamber views using Simpson’s rule. The mi-
tral valve inflow pattern will be visualised by pulsed-wave
Doppler (E/A ratio; deceleration time). Myocardial veloc-
ities obtained with tissue Doppler will be recorded using a
standard pulsed-wave Doppler technique with the sample
volume placed at the junction of the left ventricular lateral
wall with the mitral lateral annulus in the 4-chamber view.
The time interval from the onset of the P-wave in lead II to
the peak of the atrial systole (A’) at the lateral side of the
left atrium will be measured (electromechanical delay; PA-
TDI).
7-day Holter ECG
Seven-day continuous ECGs will be recorded with the
Lifecard CF® (Spacelabs Healthcare, Issaquah, WA, Unit-
ed States). This recording system allows the continuous
recording of two ECG channels for up to 7 days. Complete
recordings will be analysed with the Pathfinder SL® soft-
ware (Spacelabs Healthcare, Issaquah, WA, USA) with ad-
ditional manual confirmatory analysis. The main endpoint
will be a diagnosis of atrial fibrillation with a duration of
≥30 seconds.
24-hour Holter ECG
The same recording system as for the 7-day Holter ECG
will be used (see above). In the 24-hour Holter ECG, the
number of atrial premature complexes will be counted.
Atrial premature complexes are defined as a reduction of
the RR interval of ≥25% compared with the previous nor-
mal RR interval and with normal or aberrant QRS mor-
phology. The minimum RR coupling interval as well as
the relative reduction in the coupling interval from the pre-
vious normal RR interval (coupling interval index [CI-in-
dex]) will be calculated. The presence of non-sustained or
sustained atrial tachycardia will be noted and, if present,
the number of atrial tachycardias and longest duration in
seconds counted. Non-sustained atrial tachycardia will be
any supraventricular tachycardia of ≥3 beats up to 30 sec-
onds duration and sustained atrial tachycardia will be any
supraventricular tachycardia of ≥30 seconds duration.
30- and 60-month follow-up
The following clinical endpoints will be assessed during
follow-up by a telephone interview with all cohort patients
and/or their physicians: diagnosis of atrial fibrillation and/
or atrial flutter; death; anticoagulation therapy; acute is-
chaemic stroke or transient ischaemic attack; pacemaker or
ICD implantation.
Original article Swiss Med Wkly. 2021;151:w20421
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 9 of 9
